Plasmodium berghei ANKA: Selection of resistance to piperaquine and lumefantrine in a mouse model
| Autor: | Bernard Langat, A. Bell, V.C.S. Nyambati, Alexis Nzila, Sergio Wittlin, Jacques Chollet, Oyindamola O. Abiodun, G.M. Rukunga, Joseph K. Ng’ang’a, Beatrice Irungu, Reto Brun, Daniel Kiboi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: |
Male
Plasmodium berghei Drug Resistance Parasitemia Drug resistance Pharmacology chemistry.chemical_compound Mice 0302 clinical medicine Chloroquine Serial Passage GeneralLiterature_REFERENCE(e.g. dictionaries encyclopedias glossaries) 0303 health sciences General Medicine Artemisinins 3. Good health Infectious Diseases Ethanolamines Quinolines Female medicine.drug 030231 tropical medicine Immunology Amodiaquine Biology Lumefantrine Article 03 medical and health sciences Antimalarials Piperaquine parasitic diseases medicine Animals Cross-resistance 030304 developmental biology Fluorenes Plasmodium falciparum medicine.disease biology.organism_classification Virology Malaria Disease Models Animal chemistry Parasitology |
| Zdroj: | Experimental Parasitology |
| ISSN: | 1090-2449 0014-4894 |
| Popis: | PUBLISHED We have selected piperaquine (PQ) and lumefantrine (LM) resistant Plasmodium berghei ANKA parasite lines in mice by drug pressure. Effective doses that reduce parasitaemia by 90% (ED90) of PQ and LM against the parent line were 3.52 and 3.93 mg/kg, respectively. After drug pressure (more than 27 passages), the selected parasite lines had PQ and LM resistance indexes (I90) [ED90 of resistant line/ED90 of parent line] of 68.86 and 63.55, respectively. After growing them in the absence of drug for 10 passages and cryo-preserving them at ?80 ?C for at least 2 months, the resistance phenotypes remained stable. Cross-resistance studies showed that the PQ-resistant line was highly resistant to LM, while the LM-resistant line remained sensitive to PQ. Thus, if the mechanism of resistance is similar in P. berghei and Plasmodium falciparum, the use of LM (as part of Coartem?) should not select for PQ resistance. Irish Health Research Board (GHRA-06-03) and by the European and Developing Countries Clinical Trials Partnership (EDCTP) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect